Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Clinical, Immunological, Morphological, Molecular and Genetic Characteristics of Patients With Limb-girdle Muscular Dystrophy Type R2 (Type 2B) in the Russian Federation

NCT04824040 is registered in ClinicalTrials.gov with Artgen Biotech as lead sponsor.

NCT NCT04824040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04824040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Clinical, Immunological, Morphological, Molecular and Genetic Characteristics of Patients With Limb-girdle Muscular Dystrophy Type R2 (Type 2B) in the Russian Federation
Lead sponsor
Artgen Biotech
Phase
Observational
Overall status
Enrolling by invitation
Start date
January 15, 2020
Completion date
July 31, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dmat, dysferlinopathy, lgmdr2, miyoshi myopathy